【摘要】：目的建立肺癌人源性腫瘤組織異種移植(patient-derived tumor xenograft,PDX)裸鼠模型,檢測(cè)原代肺癌組織標(biāo)本和第三代(F3)PDX模型組織標(biāo)本內(nèi)組織形態(tài)結(jié)構(gòu)的變化和p63、napsin A和TTF-1的表達(dá)差異性。方法取臨床肺癌新鮮手術(shù)切除標(biāo)本12例,裸鼠皮下移植建立PDX模型,HE染色比較原代患者腫瘤組織與移植瘤組織結(jié)構(gòu)和細(xì)胞形態(tài)變化與否;免疫組化的方法檢測(cè)原代組織和F3代組織標(biāo)本內(nèi)p63、napsin A和TTF-1的表達(dá)水平的差異性。顯微鏡觀察。結(jié)果成功建立傳至第三代的PDX模型5例,4例肺鱗癌,1例肺腺癌。PDX模型和患者原代腫瘤具有相同的組織學(xué)特點(diǎn)和排列結(jié)構(gòu);p63在肺鱗癌患者及其PDX模型癌細(xì)胞中表達(dá)陽(yáng)性率為84.3%和96%,兩者之間差異無(wú)顯著性(P0.05),而在肺腺癌中呈陰性表達(dá)。Napsin A在肺腺癌患者及其PDX F3癌細(xì)胞中陽(yáng)性表達(dá)率分別為66%和72.4%,兩者之間差異無(wú)顯著性(P0.05)。TTF-1在肺腺癌患者及其PDX F3癌細(xì)胞中陽(yáng)性表達(dá)率分別為91%和85%,兩者之間差異也無(wú)顯著性(P0.05)。Napsin A和TTF-1在肺鱗癌中均呈陰性表達(dá)。結(jié)論本實(shí)驗(yàn)室所建立的肺癌PDX模型基本保留了部分原代腫瘤的組織學(xué)特性,為臨床前藥效的個(gè)性化篩選評(píng)估以及生物標(biāo)志物的鑒定提供了有效的研發(fā)資源。
[Abstract]:Objective to establish a nude mice model of human lung cancer tissue xenotransplantation (patient-derived tumor xenograft,PDX), and to detect the morphological changes of primary lung cancer tissue and the third generation (F3) PDX model and the difference of expression of p63, napsin A and TTF-1. Methods PDX model was established by subcutaneous transplantation in 12 fresh resected specimens of lung cancer in nude mice. HE staining was used to compare the changes of tumor tissue structure and cell morphology between primary and transplanting tumor tissues, and the expression levels of p63, napsin A and TTF-1 in primary tissues and F3 tissues were detected by immunohistochemical method. Microscopic observation. Results the third generation PDX model was successfully established in 5 cases, 4 cases of lung squamous cell carcinoma and 1 case of lung adenocarcinoma. PDX model and primary tumor had the same histologic characteristics and arrangement structure. The positive rate of p63 expression in patients with lung cancer and its PDX model cancer cells was 84.3% and 96%, respectively. There was no significant difference between the two groups (P 0.05), but the positive expression rate of napsin A was 66% and 72.4% in patients with lung cancer and its PDX F3 cancer cells, respectively. There was no significant difference between the two groups (P 0.05). The positive expression rate of TTF-1 in patients with lung cancer and its PDX F3 cancer cells was 91% and 85%, respectively, and there was no significant difference between the two groups (P 0.05). Napsin A and TTF-1 were negative in lung squamous cell carcinoma). Conclusion the PDX model of lung cancer established in our laboratory basically retains the histological characteristics of some primary tumors and provides effective research and development resources for individualized screening and evaluation of preclinical efficacy and identification of biomarkers.
【作者單位】： 南京軍區(qū)南京總醫(yī)院比較醫(yī)學(xué)科;南京軍區(qū)南京總醫(yī)院心胸外科;
【分類號(hào)】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 滕麗萍;章靜波;;異種移植模型有助于兒童抗癌[J];基礎(chǔ)醫(yī)學(xué)與臨床;2008年05期

2 盧大用,胥彬;人瘤異種移植模型研究及在癌化療中的應(yīng)用[J];國(guó)外醫(yī)學(xué).藥學(xué)分冊(cè);1984年04期

3 徐國(guó)平;;1,25-二羥維生素D_3對(duì)人癌實(shí)體瘤的異種移植瘤體內(nèi)生長(zhǎng)的抑制[J];國(guó)外醫(yī)學(xué)(衛(wèi)生學(xué)分冊(cè));1988年01期

4 甄永蘇;;人體腫瘤的異種移植與抗癌藥物研究[J];北京實(shí)驗(yàn)動(dòng)物科學(xué);1992年04期

5 吳秉銓,鄭杰,方偉崗,王潔良,惠培;人類腫瘤異種移植和癌生物學(xué)研究[J];北京醫(yī)科大學(xué)學(xué)報(bào);1989年03期

6 陳玉成;端粒酶表達(dá)同肺癌成功地異種移植間的聯(lián)系[J];中國(guó)肺癌雜志;2000年03期

7 Sharkey,F.E.;漆畹生;;在裸鼠體內(nèi)生長(zhǎng)的人類腫瘤的病理學(xué)(一)[J];上海畜牧獸醫(yī)通訊;1982年02期

8 周永華;微囊包裹腫瘤細(xì)胞異種移植的實(shí)驗(yàn)研究[J];重慶醫(yī)學(xué);1996年04期

9 梁正東，，卞度宏;微囊包裹腫瘤細(xì)胞異種移植的實(shí)驗(yàn)研究[J];重慶醫(yī)科大學(xué)學(xué)報(bào);1996年04期

10 劉情;鄭琳;張灝;;人源性腫瘤組織異種移植模型的研究進(jìn)展[J];轉(zhuǎn)化醫(yī)學(xué)雜志;2014年02期

相關(guān)會(huì)議論文 前1條

1 宋宏萍;胡浩;周曉東;;~(99m)Tc-GX1-rmhTNFα治療異種移植入胃癌腫瘤小鼠模型的綜合成像[A];中國(guó)超聲醫(yī)學(xué)工程學(xué)會(huì)第九屆全國(guó)腹部超聲醫(yī)學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2012年

相關(guān)博士學(xué)位論文 前1條

1 劉斌;諾帝抑制人橫紋肌肉瘤細(xì)胞系PLA-802及其異種移植瘤生長(zhǎng)及其機(jī)制[D];重慶醫(yī)科大學(xué);2007年

相關(guān)碩士學(xué)位論文 前2條

1 李曉明;2,3',4,5'-四甲氧基二苯乙烯對(duì)子宮內(nèi)膜癌異種移植瘤的抑制作用[D];河北醫(yī)科大學(xué);2015年

2 曾倩;免疫耐受敘利亞倉(cāng)鼠人胃癌異種移植模型傳代研究[D];河北醫(yī)科大學(xué);2006年

本文編號(hào)：2505989